A Phase 3 interventional study of Masitinib and Placebo in Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive and Multiple Sclerosis, Relapse Free, sponsored by AB Science. Completed at 8 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-04-08.
Sponsored by AB Science · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Multiple Sclerosis, Chronic Progressive with a site in France — 4 open to participants now, 10 under way, 8 of them phase 3. Multiple Sclerosis, Chronic Progressive · France.
Among the 32 studies in Multiple Sclerosis, Chronic Progressive with a site in France, this one is the 15th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2011, is one of 18 in phase 3, and was the 5th registered.
245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.
Browse Multiple Sclerosis, Chronic Progressive studies →4 of the 32 studies in Multiple Sclerosis, Chronic Progressive with a site in France are open now. Recruiting first, the newest first:
Zenas BioPharma (USA), LLC · Sites in France, United States, Australia and 17 more countries
Ages 18–60
Hoffmann-La Roche · Sites in France, Australia, Brazil and 9 more countries
Ages 18–60
Novartis Pharmaceuticals · Sites in France, United States, Argentina and 33 more countries
Ages 18–65
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–60 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 18
First in 2005; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 656 is above the median of 54 across 190 interventional studies indexed under Multiple Sclerosis, Chronic Progressive.
Median enrollment 696 across the 28 interventional studies, 277 across the 4 observational. Of the 19 that completed or were terminated, 5 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 32 have an industry lead sponsor. The 10 most frequent:
AB Science is the lead sponsor of 39 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
AB Science has 3 studies filed under Multiple Sclerosis, Chronic Progressive — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 32 studies in Multiple Sclerosis, Chronic Progressive with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the safety and efficacy of masitinib 6 mg/kg/day versus placebo in the treatment of patients with primary progressive multiple sclerosis or relapse-free secondary progressive multiple sclerosis.
Masitinib is a selective tyrosine kinase inhibitor that is thought to exert a neuroprotective effect through its activity on mast cells and other non-neuronal cells of the central nervous system, with subsequent modulation of inflammatory and neurodegenerative processes. The objective of this study is to compare the efficacy and safety of masitinib at 4.5 mg/kg/day versus matched placebo, or masitinib at 4.5 mg/kg/day with a dose escalation to 6 mg/kg/day after 3 months of treatment versus matched placebo, in the treatment of patients with primary progressive multiple sclerosis or relapse-free secondary progressive multiple sclerosis. Approximately 600 patients will be randomized into four treatment groups with a 2:2:1:1 design. The primary outcome measure is the Expanded Disability Status Scale (EDSS) after 96 weeks of treatment in the overall study population with subgroup analysis performed in stratum (primary progressive multiple sclerosis / secondary progressive multiple sclerosis).
Main inclusion criteria:
Main exclusion criteria:
Participants receive masitinib (4.5 mg/kg/day), given orally twice daily.
Drug: Masitinib
Participants receive masitinib (4.5 mg/kg/day), given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment.
Drug: Masitinib
Participants receive placebo given orally twice daily.
Drug: Placebo
Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment.
Drug: Placebo
Also known as: AB1010
Also known as: Placebo Oral Tablet
EDSS
Expanded Disability Status Scale (EDSS) after 96 weeks of treatment
Time frame: 96 weeks
MSQOL-54
Multiple Sclerosis Quality of Life 54 items (MSQOL-54)
Time frame: 96 weeks
MSFC
Multiple Sclerosis Functional Composite (MSFC)
Time frame: 96 weeks
Ran from Aug 2011 to primary completion in Sep 2019, 97 months.
Of 20 phase 3 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 83. This study's 97 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Masitinib
Multiple Sclerosis, Chronic Progressive →